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Candida nivariensis and C. bracarensis are two emerging cryptic species within the
C. glabrata complex. Thirteen of these isolates from 10 hospitals in China were
studied for their species identification and antifungal susceptibilities. Phenotypic and
molecular [rDNA ITS sequencing, D1/D2 sequencing and ITS sequencer-based capillary
gel electrophoresis (SCGE)] and matrix-assisted laser desorption ionization-time of
flight (MALDI-TOF) MS identification methods were compared for their performance in
species identification. Twelve of 13 (92.3%) isolates were identified as C. nivariensis
and one as C. bracarensis using ITS sequencing as the reference method. Results
obtained by D1/D2 sequencing and ITS SCGE were concordant with ITS sequencing
results for all (100%) isolates. SCGE was able to subtype 12 C. nivariensis into four
ITS SCGE length types. All isolates failed to be identified by the Vitek MALDI-TOF
MS system (bioMérieux), whilst the Bruker MS system (Bruker Daltoniks) correctly
identified all C. nivariensis isolates but using a lowered (≥1.700) cut-off score for
species assignment; the C. bracarensis isolate was identified but with score <1.700.
The Vitek 2 Compact system could not identify 11 C. nivariensis and one C. bracarensis
isolate and misidentified the remaining C. nivarensis strain as “C. glabrata.” All isolates
were susceptible-dose dependent to fluconazole [minimum inhibitory concentration
(MIC) range 0.5–4 µg/mL] and were classed as susceptible to echinocandins
(MICs ≤ 0.06 µg/mL). All 13 isolates had low MICs for other azoles (MICs ≤ 0.5 µg/mL),
amphotericin B (MICs ≤ 2 µg/mL) and 5-flucytosine (MICs ≤ 0.25 µg/mL). Our
results reinforce the need for molecular differentiation of species of C. nivarensis and
C. bracarensis. The performance of MALDI-TOF may be improved by adding mass
spectral profiles (MSPs) into the current databases. The antifungal susceptibility profile
of isolates should be monitored.
Keywords: Candida nivariensis, Candida bracarensis, ITS sequencing, D1/D2 sequencing, ITS sequencer-based
capillary gel electrophoresis (SCGE), matrix-assisted laser desorption ionization-time of flight mass spectrometry
(MALDI-TOF), antifungal susceptibility
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INTRODUCTION
Candida remains the most important cause of opportunistic
mycoses worldwide (Pfaller and Diekema, 2007). Although
overall, C. albicans remains the most common Candida species
responsible for invasive candidiasis, non-albicans Candida
species increasingly represent a significant burden (Pfaller
et al., 2010). With evolving and changing fungal taxonomy
due to advances in DNA sequencing techniques, previously
unrecognized species, as well as “cryptic” species within species
complexes have been identified. Examples include the distinction
between closely related species within the C. parapsilosis
species complex (C. parapsilosis sensu stricto, C. orthopsilosis
and C. metapsilosis), C. haemulonii complex (C. haemulonii,
C. duobushaemulonii and C. haemulonii var. vulnera) and
C. glabrata complex (C. glabrata sensu stricto, C. nivariensis and
C. bracarensis; Alcoba-Florez et al., 2005; Tavanti et al., 2005;
Correia et al., 2006; Cendejas-Bueno et al., 2012).
Although cryptic species of the C. glabrata complex likely
cause similar disease manifestations as C. glabrata sensu stricto,
their distinction is important due to differences in antifungal
susceptibility where both C. nivariensis and C. bracarensis have
been reported to be more drug resistant including to the
azoles (Fujita et al., 2007; Bishop et al., 2008; Borman et al.,
2008; Figueiredo-Carvalho et al., 2016). However, phenotypic
identification methods cannot identify these two species where
they are “misidentified” as “C. glabrata” by identification systems
such as Vitek 2 Compact system and API ID32C (bioMérieux,
Marcy l’Etoile, France; Alcoba-Florez et al., 2005; Correia et al.,
2006; Lockhart et al., 2009). Matrix-assisted laser desorption
ionization–time of flight mass spectrometry (MALDI-TOF MS)
is able to rapidly and accurately identify Candida species (Pinto
et al., 2011). The mass spectra (MS) of C. glabrata sensu stricto,
C. nivariensis and C. bracarensis are included in most commercial
MS databases (Pinto et al., 2011; Gorton et al., 2013). Nonetheless,
confirmation of species identification remains reliant on DNA
sequencing of the fungal rDNA ITS region (considered the
reference method) or the D1/D2 region of the 28S rRNA gene in
many instances (Alcoba-Florez et al., 2005; Correia et al., 2006).
Other molecular methods may also be employed to identify
and distinguish within C. glabrata species complex including an
ITS-targeted SCGE method. We had previously used SCGE to
distinguish between subtypes of both C. glabrata (cgl-1 and cgl-2)
and C. nivariensis (cni-1 and cni-2; Hou et al., 2016).
Despite growing awareness of their clinical significance,
data on the occurrence and distribution of C. nivariensis and
Abbreviations: 5FC, 5-flucytosine; AF, ascitic fluid; AMB, amphotericin B;
ANF, anidulafungin; BAL, bronchoalveolar lavage fluid; CAS, caspofungin; CBPs,
clinical breakpoints; cbr, C. bracarensis; CHIF-NET, China Hospital Invasive
Fungal Surveillance Net; CLSI, Clinical and Laboratory Standards Institute; cni,
C. nivariensis; CSF, cerebrospinal fluid; ECVs, epidemiological cut-off values;
FLC, fluconazole; ICU, intensive care unit; IFDs, invasive fungal diseases;
ITC, itraconazole; ITS LTs, ITS length types; ITS, internal transcribed spacer;
MALDI-TOF, matrix-assisted laser desorption ionization-time of flight; MCF,
micafungin; MIC, minimum inhibitory concentration; MSPs, mass spectral
profiles; NI, no identification; POS, posaconazole; SCGE, sequencer-based capillary
gel electrophoresis; S-DD, susceptible-dose dependent; STs, sequence types; UN,
unkown; VRC, voriconazole.
C. bracarensis in clinical specimens in China has not been
described. Therefore, here we have studied the epidemiology
and antifungal susceptibility of C. nivariensis and C. bracarensis
clinical isolates collected from a multi-center surveillance in
China over 5 years.
MATERIALS AND METHODS
Ethics Statement
The study was approved by the Human Research Ethics
Committee of Peking Union Medical College Hospital (No.
S-263). Written informed consent was obtained from patients for
the use of the samples in research.
Yeast Isolates
All isolates were collected as part of the nationwide surveillance
program for IFDs in China -CHIF-NET from August 2009 to July
2014 (Table 1). The CHIF-NET was a nationwide, prospective,
laboratory-based, surveillance network established to provide
updated information on the epidemiology of IFDs in China and
the study inclusion criteria are previously described (Wang et al.,
2012). Isolates were collected from different study centres and
then forwarded to a central reference laboratory (Department
of Clinical Laboratory, Peking Union Medical College Hospital)
for species identification. Species were identified at study
sites but confirmed in all cases at the reference laboratory.
Specifically, species identification was performed by MALDI-
TOF MS and by sequencing of the ITS region according to
the algorithm of Zhang et al. (2014). All isolates identified as
“C. glabrata” and all uncommon or interesting Candida species
were also identified by sequencing of the ITS regions. Over
8000 Candida isolates were collected during 5 years and a total
of 12 C. nivariensis and one C. bracarensis were identified.
Then phenotypic and molecular (rDNA ITS sequencing, D1/D2
sequencing and ITS SCGE) and MALDI-TOF MS identification
methods were compared and evaluated for their performance in
species identification.
Vitek 2 Compact System Identification
All 13 isolates were also re-identified using the Vitek-2 yeast
identification card (Vitek-2 Yeast ID; bioMérieux, Marcy l’Etoile,
France) following the manufacturer’s instructions. The inoculum
suspensions for the Vitek 2 were prepared in sterile saline
at turbidity equal to a 2.0 McFarland standard, as measured
using a DensiChek instrument (bioMérieux). The individual
test cards were automatically filled with the prepared culture
suspension, sealed, and incubated by the Vitek 2 instrument.
Cards were incubated for 18 h at 35◦C and read every
15 min. The final profile results were compared with the
database, and the identification of the unknown organism was
obtained.
Sequencer-Based Identification
(i) For DNA sequencing, all isolates were identified by
sequencing the ITS region gene and the D1/D2 domain of
the 28S rRNA gene was performed as previously described
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(Amberg et al., 2005; Zhang et al., 2014). The ITS region
and D1/D2 sequences of strains used in this study have been
deposited in GenBank (Supplementary Table S1).
(ii) For ITS SCGE, both the ITS1 and full-length ITS regions
of each isolate were amplified by a duplex PCR as previously
described (Hou et al., 2016).
Phylogenetic Analysis
ITS and D1/D2 nucleotide sequences of C. nivariensis and
C. bracarensis were obtained from GenBank (Supplementary
Table S1). C. glabrata ATCC 2001 was also included. The ITS and
D1/D2 sequences were then used for phylogenetic analysis by the
maximum-likelihood algorithm with 1000 bootstrap replication
to ensure robustness using MEGA software (version 6.0, MEGA
Inc., Englewood, NJ, USA).
Matrix-Assisted Laser Desorption
Ionization-Time of Flight Mass
Spectrometry (MALDI-TOF MS) Analysis
All isolates were identified by both Vitek MS system (IVD
Knowledgebase version 2.0, bioMérieux, Marcy l’Etoile, France)
and Bruker Autoflex Speed TOF/TOF MS system using Biotyper
version 3.1 software (Bruker Daltoniks, Billerica, MA, USA)
according to the manufacturer’s instructions. For the Vitek MS
system, the results were scored in one of three ways, (i) a
single identification (confidence value of 60.0 to 99.9%), (ii)
a split identification for which a set of possible organisms is
displayed, or (iii) NI when no match is found (Zhang et al.,
2014). C. nivariensis and C. bracarensis reference spectra are
not included in the Vitek MS v2.0 database. With the Bruker
system, identification was provided according to manufacturer-
determined criteria: a spectral score of <1.700 was considered
not to provide reliable identification. A score of 1.700 but
<2.000 indicated identification at the genus level, and a score
of ≥2.000, identification at the species level (Deak et al., 2015).
The current Bruker Daltonik v3.1 database contains 5,989
MSPs, which include reference spectra of C. nivariensis and
C. bracarensis.
Antifungal Susceptibility Testing
The in vitro susceptibility to nine antifungal drugs – FLC, VRC,
ITC, POS, CAS, MCF, ANF, AMB and 5FC – was determined
using Sensititre YeastOneTM YO10 methodology (Thermo
Scientific, Cleveland, OH, USA) following the manufacturer’s
instructions. Briefly, isolates were sub-cultured onto Sabouraud
dextrose agar (Oxoid Ltd., Hampshire, UK) and incubated at
35◦C for 48 h. After this, 20µL of 0.5 McFarland yeast suspension
was transferred into 11 mL of inoculum broth and then 100 µL
of the inoculated broth was transferred to each well of the
manufacturer’s plate. Plates were incubated at 35◦C and the
MIC endpoints were read at 24 h. C. krusei ATCC 6258 and
C. parapsilosis ATCC22019 were used as quality control strains
in every test run. For C. glabrata complex, MIC values were
interpreted according to the CBPs for FLC and echinocandins
according to the CLSI M27-S4 standard, and to ECVs for the
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other agents (Clinical and Laboratory Standards Institute, 2012;
Pfaller and Diekema, 2012).
Review of C. nivariensis and
C. bracarensis Infections Reported in
PubMed
For comprehensive understanding of the current epidemiology
and antifungal susceptibility profiles of C. nivariensis and
C. bracarensis, we reviewed and summarized all published
literature in PubMed1 database as of July 12, 2016.
RESULTS
Detailed information relating to the study isolates is summarized
in Table 1. The 13 isolates were collected from 13 patients
at 10 hospitals situated in eight provinces across China. For
C. nivariensis, 25% (3/12) of the isolates were from patients
admitted in the surgery department, 25% (3/12) from the ICU,
25% (3/12) from neonatology department, and the remaining
25% (3/12) were from other departments. The C. bracarensis
isolate was grown from pus from a patient admitted to the
surgery department in 2012 (Table 1). C. nivariensis recovered
from blood cultures comprised 75% (9/12) of the strains with
two isolates (2/12, 16.7%) recovered from CSF and one (8.3%)
from AF.
1http://www.ncbi.nlm.nih.gov/pubmed
Species Identification of C. nivariensis
and C. bracarensis by Sequencer-Based
Identification
The ITS sequences of the 13 study isolates exhibited
98.6 to 99.7% and 98.5% sequence identity to ITS
sequences of reference isolates archived in the GenBank
database (C. nivariensis CBS 10161 and C. bracarensis
153MT; Supplementary Table S1). Twelve isolates were
identified as C. nivariensis and one as C. bracarensis
(Table 1).
Analysis of the D1/D2 gene region sequences identified
all 13 clinical isolates with 100% concordance with ITS
sequencing results (Table 1). The D1/D2 region sequence
of the 12 C. nivariensis isolate (KX499363 to KX499375)
showed 99.6% sequence identity to those of C. nivariensis
isolates in GenBank (C. nivariensis CBS 10161, accession no.
EF056323.1) and the C. bracarensis sequence showed 99.7%
sequence identity to that of C. bracarensis 153MT (accession
no. AY589572.1). Results of ITS SCGE identified lengths
of ITS1 and full-length ITS regions for C. nivariensis and
C. bracarensis, which were identified as “cni-1,” “cni-2,” “cni-
3,” “cni-4” and “cbr-1” as previously described (Hou et al.,
2016).
Phylogenetic Analysis
The nucleotide sequence alignments within C. nivariensis and
C. bracarensis, with reference to sequences of C. nivariensis
type strain CBS 10161 and C. bracarensis type strain 153MT
FIGURE 1 | The maximum-likelihood tree of C. nivariensis and C. bracarensis with ITS sequences available in GenBank, using Candida albicans
ATCC 18804 as an outgroup.
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FIGURE 2 | The maximum-likelihood tree of C. nivariensis and C. bracarensis with D1/D2 sequences available in GenBank, using Candida albicans
ATCC 18804 as an outgroup.
as the reference points, showed these species had high inter-
species genetic similarity within ITS region (98.4 to 100%) and
D1/D2 region (98.1 to 99.8%; Supplementary Table S1). The
maximum-likelihood analysis of the ITS and D1/D2 region
yielded similar results (Figures 1 and 2). For ITS, three groups
of C. nivariensis were distinguished and our 12 isolates were in
Groups I and II (Figure 1). Intra-species ITS diversity in Candida
species has been described before (Merseguel et al., 2015).
There was no intra-species D1/D2 diversity in 12 C. nivariensis
isolates (Figure 2). Both ITS and D1/D2 sequencing can be
used for the differentiation of C. glabrata, C. nivariensis and
C. bracarensis.
Performance of Vitek-2 Compact and
Two MALDI-TOF MS Systems
As compared with ITS sequencing, 11 C. nivariensis and the
C. bracarensis isolates could not be identified by the Vitek 2
Compact system (bioMérieux). The remaining C. nivariensis was
misidentified as C. glabrata (score = 94%; Table 1). All isolates
were not identified by the Vitek MS system because C. nivariensis
and C. bracarensis reference spectra were not included in the
Vitek MS v2.0 database (Table 1). However, the Bruker system
correctly identified all C. nivariensis isolates to the genus level
with a MS score of <2.000 but ≥1.700. The C. bracarensis isolate
was identified as such but with a MS score of 1.447 (Table 1).
Antifungal Susceptibility
The antifungal susceptibilities of the study isolates to nine
antifungal agents are shown in Table 2. All isolates were
S-DD to FLC (MIC range 0.5–4 µg/mL) and were classed as
susceptible to echinocandins (MICs ≤ 0.06 µg/mL). All 13
isolates were also wild type to VRC (MICs ≤ 0.12 µg/mL),
ITC (MICs ≤ 0.25 µg/mL), POS (MICs ≤ 0.5 µg/mL), AMB
(MICs ≤ 2 µg/mL) and 5FC (MICs ≤ 0.25 µg/mL).
C. nivariensis and C. bracarensis
Reported in PubMed
By searching the literature in PubMed1 using “C. nivariensis
or C. bracarensis” as the keywords, a total of 46 articles were
found as of July 12, 2016. Among these, 15 and seven, full
text articles reporting on the detection of C. nivariensis and
C. bracarensis isolates were found, respectively; with 65 cases
identified in 12 regions and 16 cases identified in seven regions,
respectively (Supplementary Table S1). C. nivariensis caused
mucosal superficial disease as well as IFDs and have been isolated
from body sites including the mouth, toenails, urine, sputum,
vagina, CSF, blood, BAL and other sterile body fluids. Two
C. nivariensis isolates have been recovered from soil and bark.
C. bracarensis has been isolated from throat, stool, abscess,
sputum, vagina, blood and other sterile body fluids.
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TABLE 2 | In vitro susceptibility of 12 Candida nivariensis and one Candida bracarensis to nine antifungal agents.
Strain or parameter MIC (µg/mL)
ANF MCF CAS 5FC POS VRC ITC FLC AMB
C. nivariensis
10HX033 0.03 ≤0.008 0.03 0.25 0.25 0.03 0.12 1 2
10HX034 0.06 0.015 0.03 0.12 0.25 0.03 0.12 1 1
12HB004 0.03 0.015 0.03 0.12 0.12 0.015 0.12 0.5 1
12TZ215 0.06 0.015 0.06 0.25 0.25 0.03 0.12 0.5 1
13J3030 0.015 ≤0.008 0.06 0.12 0.12 0.03 0.06 1 0.5
13H4102 0.03 0.03 0.06 0.12 0.5 0.03 0.12 0.5 1
13H1295 0.03 0.015 0.03 0.25 0.25 0.06 0.25 2 2
13JX046 0.06 0.015 0.06 0.25 0.12 0.03 0.12 1 1
13AH035 0.06 0.015 0.06 0.12 0.25 0.03 0.12 1 1
13AH037 0.06 0.015 0.06 0.12 0.25 0.015 0.12 1 1
13AH038 0.06 0.015 0.06 0.25 0.25 0.03 0.12 1 2
13W3020 0.06 0.015 0.06 0.25 0.5 0.12 0.25 4 1
MIC range 0.015−0.06 ≤0.008−0.03 0.03−0.06 0.12−0.25 0.12−0.5 0.015−0.12 0.06−0.25 0.5−4 0.5−2
MIC50 0.06 0.015 0.06 0.12 0.25 0.03 0.12 1 1
MIC90 0.06 0.015 0.06 0.25 0.5 0.06 0.25 2 2
GM 0.04 0.01 0.05 0.17 0.23 0.03 0.13 1 1.12
C. bracarensis
12NX009 0.03 0.015 0.03 0.25 0.25 0.03 0.12 1 2
FLC, fluconazole; VRC, voriconazole; ITC, itraconazole; POS, posaconazole; CAS, caspofungin; MCF, micafungin; ANF, anidulafungin; AMB, amphotericin B; 5FC, 5-
flucytosine.
Data on C. nivariensis (12 articles were found) and
C. bracarensis (six articles) antifungal susceptibility profiles
are relatively limited. An overview of the published data is
presented in Supplementary Table S2. Some strains exhibited
high MICs to FLC alone or to all azoles, suggesting that the
same mechanisms of resistance as found in C. glabrata may
be involved (Fujita et al., 2007; Bishop et al., 2008; Borman
et al., 2008; Gorton et al., 2013; Figueiredo-Carvalho et al.,
2016). Further studies, using the C. nivariensis and C. bracarensis
genome data, that are now available, might be useful to
confirm this hypothesis (Angoulvant et al., 2016). MICs to
echinocandins of C. nivariensis and C. bracarensis are overall
low (MIC90 < 0.5 µg/ml for CAS; Supplementary Table S2). To
date there are no reports on emergence of echinocandin-resistant
C. nivariensis or C. bracarensis strains.
DISCUSSION
Candida nivariensis and C. bracarensis are reportedly uncommon
amongst clinical Candida isolates. Although the three species
are closely related phylogenetically, DNA sequencing has shown
that C. glabrata, C. nivariensis and C. bracarensis are sufficiently
genetically distinct to justify their assignment as separate species
(Figures 1 and 2) (Alcoba-Florez et al., 2005; Correia et al., 2006;
Mirhendi et al., 2011).
In the present study, we have estimated the proportion
of C. nivariensis and C. bracarensis amongst Candida strains
cultured from patient with IFDs in China. Overall, during the
5-year CHIF-NET study period, C. nivariensis and C. bracarensis
collectively represented only 0.11% (13/9673) of all yeast
isolates, while 947 (9.79%, 947/9673) C. glabrata were collected.
Among the 13 isolates, C. nivariensis (12/9673) was more
frequently isolated compared with C. bracarensis (1/9673),
which is in accordance with a retrospective study from four
French university hospitals (2010–2014) where C. nivariensis and
C. bracarensis were, respectively, identified in 0.12 and 0.01% of
the 55,464 yeast strains (Angoulvant et al., 2016). Conversely,
in the ARTEMIS DISK Global Antifungal Surveillance Study
(2001–2006), where a total of 1,598 isolates phenotypically
identified as C. glabrata were re-tested by peptide nucleic acid
fluorescence in situ hybridization, only one C. nivariensis and
two C. bracarensis were identified (Lockhart et al., 2009). In a
Spanish study over a period of 2 years (2008–2009), a total of
three (2%) of 143 C. glabrata clinical strains were identified as
C. bracarensis and none as C. nivariensis (Cuenca-Estrella et al.,
2011). Data for prevalence of C. nivariensis and C. bracarensis
are directly influenced by the identification method used and
comparisons between studies need to take into account the
different identification methodologies used. In this study we have
reinforced that molecular methods are the preferred approach
for definitive identification of members within the species
complex. Currently, ITS and D1/D2 regions were considered as
universal DNA barcode markers for Candida spp. identification
(Taverna et al., 2013). In this study, ITS sequencing was able
to identify all 13 isolates and of note, concordance of results
with ITS sequencing was 100% with those obtained by D1/D2
sequencing and ITS SCGE. An ITS SCGE assay has also shown
promise for identification of these cryptic species and indeed to
identify subtypes within these species. Twelve C. nivariensis were
Frontiers in Microbiology | www.frontiersin.org 6 January 2017 | Volume 8 | Article 5
fmicb-08-00005 January 17, 2017 Time: 16:47 # 7
Hou et al. Candida nivariensis and Candida bracarensis in China
subtyped into four different ITS LTs, i.e., five cni-1, five cni-2, one
cni-3 and one cni-4. The technique has the advantage of being
simple to use (Hou et al., 2016).
Conventional phenotypic-based methods of classification of
species within the C. glabrata complex have proven ineffective
in accurately identifying these species as was the case in the
present study (Alcoba-Florez et al., 2005; Correia et al., 2006),
where all 13 isolates could not be identified by the Vitek 2 system
(bioMérieux), except for one isolate “misidentified” asC. glabrata.
Hence any unusual identification result should be confirmed
by an alternative more discriminatory method. One simple
method is to visualize the color of colonies on CHROMagar
(Becton Dickinson, Heidelberg, Germany). C. nivariensis and
C. bracarensis isolates yield white colonies on CHROMagar in
contrast to the purple colonies of C. glabrata (Lockhart et al.,
2009), and may be useful as a screen for members of the
C. glabrata clade.
MALDI-TOF MS has become a routine identification tool
for the identification of yeast and yeast-like organisms in many
laboratories (Pinto et al., 2011; Gorton et al., 2013). In one
study, four isolates collected from vagina were identified as
C. nivariensis by the Bruker MS system (Bruker Daltoniks),
with a log score between 1.802 and 2.086 (Aznar-Marin et al.,
2015). MALDI-TOF MS has been reported to have the ability to
distinguish within the C. glabrata clade, i.e., between C. glabrata,
C. nivariensis and C. bracarensis, with scores of <1.700 as
C. nivariensis (3/10 strains) and C. bracarensis (1/1 strain;
Pinto et al., 2011). We found the database of the Vitek MS
system (bioMérieux; IVD Knowledgebase version 2.0) to be
limited by the absence of reference spectra for C. nivariensis
and C. bracarensis. In comparison, the Bruker system (Bruker
Daltoniks) was able to distinguish between all three members
of the C. glabrata complex; the log scores of all C. nivariensis
isolates were >1.700 but <2.000, while the log score of the
C. bracarensis isolate was <1.700. The current Bruker Daltonik
v3.1 database contains six MSPs for C. nivariensis and two MSPs
for C. bracarensis. The addition of further reference spectra to
the database may improve the utility of MALDI-TOF MS-based
identification (Pinto et al., 2011). To improve the identification
capacity of MALDI-TOF MS, it is important for MS databases to
contain more reference mass spectra from type strains of different
species, and also spectra representing different strains of the same
species (Singhal et al., 2015).
Accurate identification of C. nivariensis and C. bracarensis
in clinical samples is important, because the antifungal
susceptibility patterns of C. nivariensis and C. bracarensis may
differ from that of C. glabrata. In vitro susceptibility to azoles
and 5FC appears to be lower for C. nivariensis than for
C. glabrata (Fujita et al., 2007; Bishop et al., 2008; Borman
et al., 2008). Although our isolates had low MICs to the
azoles, echinocandins, AMB and 5FC, several studies have
reported azoles resistance in these two species (Fujita et al.,
2007; Bishop et al., 2008; Borman et al., 2008; Gorton et al.,
2013; Figueiredo-Carvalho et al., 2016). For C. nivariensis, the
MICs range of FLC has been 0.5 – >256 µg/ml, ITC MICs
range 0.03 – >16 µg/ml, while the MICs range of FLC of
C. bracarensis was 2–256 µg/ml and for ITC, 0.06 – >16 µg/ml
(Supplementary Table S2). All isolates reported thus far have
been susceptible to the echinocandins. Additional strains of
C. nivariensis and C. bracarensis need to be studied to better
understand their susceptibility profile and to determine whether
these species have clinically significant differences in responses
to antifungal therapy compared to C. glabrata. Moreover, studies
from multiple geographical locations are needed to elucidate the
epidemiology of infection, colonization and antifungal resistance
of C. nivariensis and C. bracarensis.
SUMMARY
This is the first systemic study regarding the epidemiology,
identification and antifungal susceptibility profiles of
C. nivariensis and C. bracarensis isolates in China. Our study
reinforces the need for molecular identification of these two
new and rarely species. Further improvements in the MALDI-
TOF databases are needed to increase the identification accuracy.
Studies from multiple geographical locations and additional data
are required to better characterize their frequency, geographical
distribution, susceptibility profiles and clinical features of
infections due to C. nivariensis and C. bracarensis.
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